Comparative Pharmacology
Head-to-head clinical analysis: GASTROVIST versus IOPAMIDOL 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROVIST versus IOPAMIDOL 370.
GASTROVIST vs IOPAMIDOL-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrovist (diatrizoate meglumine) is a iodinated radiographic contrast agent that attenuates X-rays, enhancing visualization of the gastrointestinal tract. It acts as a hyperosmolar agent, drawing fluid into the bowel lumen and providing positive contrast for imaging.
Iopamidol is a nonionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. Its mechanism is physical rather than pharmacological, based on iodine content and osmolality.
Oral: 50-100 mL of a 30% w/v solution (300 mg iodine/mL) administered orally 30-60 minutes before imaging. Repeat dose if necessary for adequate visualization. Rectal: 100-200 mL of a 30% w/v solution as enema for CT colonography.
1-2 mL/kg (370 mg iodine/mL) IV up to a maximum of 150 mL per procedure for contrast-enhanced CT; for angiography, dose varies by procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function. Prolonged to 10-70 hours in patients with renal impairment, necessitating dose adjustment or avoidance.
Primarily renal (glomerular filtration): >95% of iodinated contrast is excreted unchanged in urine within 24 hours; <5% fecal or biliary.
Primarily renal; >90% of administered dose excreted unchanged in urine via glomerular filtration within 24-48 hours. Less than 1% excreted in feces or bile.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent